# Westwater Resources, Inc.: financial statements, quarterly

WWR · NYSE · CIK 839470 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wwr.md) · [Financials](/companies/wwr/financials.md) · [Filings](/companies/wwr/filings.md) · [Insiders](/companies/wwr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wwr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.0](/filings/0001558370-24-015722.md) | [0.3 d](/filings/0001558370-25-003382.md) | [0.3](/filings/0001558370-25-007769.md) | [0.3](/filings/0001558370-25-011384.md) | [0.3](/filings/0001104659-25-110396.md) | [0.3 d](/filings/0001104659-26-032111.md) | [0.2](/filings/0001104659-26-059442.md) | [0.3](/filings/0001104659-26-092955.md) | [0.4](/filings/0001104659-25-110396.md) | [0.3 d](/filings/0001104659-26-032111.md) | [0.6](/filings/0001104659-26-059442.md) | [0.4](/filings/0001104659-26-092955.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.5)](/filings/0001558370-24-015722.md) | [1.8 d](/filings/0001558370-25-003382.md) | [(2.9)](/filings/0001558370-25-007769.md) | [(3.8)](/filings/0001558370-25-011384.md) | [(3.1)](/filings/0001104659-25-110396.md) | [(2.8) d](/filings/0001104659-26-032111.md) | [(2.7)](/filings/0001104659-26-059442.md) | [(3.9)](/filings/0001104659-26-092955.md) | [(9.8)](/filings/0001104659-25-110396.md) | [(10.9) d](/filings/0001104659-26-032111.md) | [(4.7)](/filings/0001104659-26-059442.md) | [(4.3)](/filings/0001104659-26-092955.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001558370-24-015722.md) | not reported | [(0.05)](/filings/0001558370-25-007769.md) | [(0.07)](/filings/0001558370-25-011384.md) | [(0.05)](/filings/0001104659-25-110396.md) | not reported | [(0.04)](/filings/0001104659-26-059442.md) | [(0.05)](/filings/0001104659-26-092955.md) | [(0.12)](/filings/0001104659-25-110396.md) | not reported | [(0.04)](/filings/0001104659-26-059442.md) | [(0.03)](/filings/0001104659-26-092955.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001558370-24-015722.md) | not reported | [(0.05)](/filings/0001558370-25-007769.md) | [(0.07)](/filings/0001558370-25-011384.md) | [(0.05)](/filings/0001104659-25-110396.md) | not reported | [(0.04)](/filings/0001104659-26-059442.md) | [(0.05)](/filings/0001104659-26-092955.md) | [(0.12)](/filings/0001104659-25-110396.md) | not reported | [(0.04)](/filings/0001104659-26-059442.md) | [(0.03)](/filings/0001104659-26-092955.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: not reported
- Interest expense: not reported
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.7](/filings/0001558370-23-019042.md) | [10.9](/filings/0001558370-25-003382.md) | [6.1](/filings/0001558370-24-008136.md) | [3.2](/filings/0001558370-24-012233.md) | [4.5](/filings/0001558370-24-015722.md) | [4.3](/filings/0001104659-26-032111.md) | [3.3](/filings/0001558370-25-007769.md) | [6.7](/filings/0001558370-25-011384.md) | [12.9](/filings/0001104659-25-110396.md) | [48.6](/filings/0001104659-26-092955.md) | [41.5](/filings/0001104659-26-059442.md) | [38.2](/filings/0001104659-26-092955.md) |
| Current assets | $m | [12.2](/filings/0001558370-23-019042.md) | [11.6](/filings/0001558370-25-003382.md) | [7.0](/filings/0001558370-24-008136.md) | [7.7](/filings/0001558370-24-012233.md) | [5.7](/filings/0001558370-24-015722.md) | [4.9](/filings/0001104659-26-032111.md) | [4.2](/filings/0001558370-25-007769.md) | [7.3](/filings/0001558370-25-011384.md) | [13.4](/filings/0001104659-25-110396.md) | [48.9](/filings/0001104659-26-092955.md) | [42.3](/filings/0001104659-26-059442.md) | [38.8](/filings/0001104659-26-092955.md) |
| Total assets | $m | [148](/filings/0001558370-23-019042.md) | [150](/filings/0001558370-25-003382.md) | [147](/filings/0001558370-24-008136.md) | [144](/filings/0001558370-24-012233.md) | [143](/filings/0001558370-24-015722.md) | [146](/filings/0001104659-26-032111.md) | [147](/filings/0001558370-25-007769.md) | [150](/filings/0001558370-25-011384.md) | [158](/filings/0001104659-25-110396.md) | [195](/filings/0001104659-26-092955.md) | [189](/filings/0001104659-26-059442.md) | [186](/filings/0001104659-26-092955.md) |
| Current liabilities | $m | [8.9](/filings/0001558370-23-019042.md) | [7.8](/filings/0001558370-25-003382.md) | [7.3](/filings/0001558370-24-008136.md) | [7.8](/filings/0001558370-24-012233.md) | [9.4](/filings/0001558370-24-015722.md) | [11.8](/filings/0001104659-26-032111.md) | [11.1](/filings/0001558370-25-007769.md) | [14.3](/filings/0001558370-25-011384.md) | [18.3](/filings/0001104659-25-110396.md) | [11.6](/filings/0001104659-26-092955.md) | [9.1](/filings/0001104659-26-059442.md) | [7.6](/filings/0001104659-26-092955.md) |
| Total liabilities | $m | [10.6](/filings/0001558370-23-019042.md) | [9.4](/filings/0001558370-25-003382.md) | [8.9](/filings/0001558370-24-008136.md) | [9.4](/filings/0001558370-24-012233.md) | [11.0](/filings/0001558370-24-015722.md) | [13.2](/filings/0001104659-26-032111.md) | [12.6](/filings/0001558370-25-007769.md) | [15.7](/filings/0001558370-25-011384.md) | [19.7](/filings/0001104659-25-110396.md) | [13.0](/filings/0001104659-26-092955.md) | [10.4](/filings/0001104659-26-059442.md) | [8.9](/filings/0001104659-26-092955.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [137](/filings/0001558370-24-015722.md) | [140](/filings/0001104659-26-032111.md) | [138](/filings/0001558370-25-011384.md) | [135](/filings/0001104659-25-110396.md) | [133](/filings/0001104659-25-110396.md) | [133](/filings/0001104659-26-092955.md) | [135](/filings/0001104659-26-092955.md) | [135](/filings/0001104659-26-092955.md) | [138](/filings/0001104659-25-110396.md) | [182](/filings/0001104659-26-092955.md) | [179](/filings/0001104659-26-092955.md) | [177](/filings/0001104659-26-092955.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,267) d](/filings/0001558370-24-015722.md) | [757 d](/filings/0001558370-25-003382.md) | [(2,776)](/filings/0001558370-25-007769.md) | [(2,405) d](/filings/0001558370-25-011384.md) | [1,421 d](/filings/0001104659-25-110396.md) | [(2,054) d](/filings/0001104659-26-032111.md) | [(2,310)](/filings/0001104659-26-059442.md) | [(2,363) d](/filings/0001104659-26-092955.md) | [(3,260) d](/filings/0001104659-25-110396.md) | [(1,964) d](/filings/0001104659-26-032111.md) | [(4,042)](/filings/0001104659-26-059442.md) | [(2,506) d](/filings/0001104659-26-092955.md) |
| Capital expenditure | $k | [3,434 d](/filings/0001558370-24-015722.md) | [3,003 d](/filings/0001558370-25-003382.md) | [2,491](/filings/0001558370-25-007769.md) | [1,481 d](/filings/0001558370-25-011384.md) | [1,064 d](/filings/0001104659-25-110396.md) | [1,110 d](/filings/0001104659-26-032111.md) | [2,932](/filings/0001104659-26-059442.md) | [2,125 d](/filings/0001104659-26-092955.md) | [1,184 d](/filings/0001104659-25-110396.md) | [5,447 d](/filings/0001104659-26-032111.md) | [1,554](/filings/0001104659-26-059442.md) | [729 d](/filings/0001104659-26-092955.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.5](/filings/0001558370-23-019042.md) | [49.4](/filings/0001558370-24-008136.md) | [51.1](/filings/0001558370-24-012233.md) | [53.0](/filings/0001558370-24-015722.md) | [56.1](/filings/0001558370-25-007769.md) | [57.4](/filings/0001558370-25-011384.md) | [58.4](/filings/0001104659-25-110396.md) | [67.9](/filings/0001104659-26-059442.md) | [76.0](/filings/0001104659-26-092955.md) | [85.4](/filings/0001104659-25-110396.md) | [123](/filings/0001104659-26-059442.md) | [127](/filings/0001104659-26-092955.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 128,564,833 at 2026-08-10, from the cover of the [10-Q filed 2026-08-10](/filings/0001104659-26-092955.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.